On the other hand, the concept of non-genomic or cytoplasmic response was introduced in 1967, when Szego and Davis observed an increase in cyclic adenosine monophosphate (cAMP) in the MCF-7 breast cancer cell line pretreated with estrogens (Szego and Davis, 1967)
But because the GLP-1s are delivering such incredible resultsfor weight loss, diabetes, cardiovascular disease, liver disease, kidney disease, etc.there seem to be fears that this cant be real or this cant be free. As in, the outcomes are so good, they must be too good to be true
Unlike injections, oral GLP-1 medications must pass through the digestive system before being absorbed
No clinically significant drug interaction appears in FDA labeling or major databases
Research suggests that dose response varies widely
Markets Europe Markets China Markets Asia Markets World Markets Currencies Prediction Markets Cryptocurrency Futures & Commodities Bonds Funds & ETFs Business Economy Finance Health & Science Media Real Estate Energy Climate Transportation Investigations Industrials Retail Wealth Sports Life Small Business Investing Personal Finance Fintech Financial Advisors Options Action ETF Street Buffett Archive Earnings Trader Talk Tech Cybersecurity AI Enterprise Internet Media Mobile Social Media CNBC Disruptor 50 Tech Guide Politics White House Policy Defense Congress Expanding Opportunity Europe Politics China Politics Asia Politics World Politics Video Latest Video Full Episodes Livestream Top Video Live Audio Europe TV Asia TV CNBC Podcasts CEO Interviews Digital Originals Watchlist Investing Club Trust Portfolio Analysis Trade Alerts Meeting Videos Homestretch Jim's Columns Education Subscribe PRO Pro News Josh Brown Mike Santoli Calls of the Day My Portfolio Livestream Full Episodes Stock Screener Market Forecast Options Investing Chart Investing Subscribe Livestream Make It select USA INTL Livestream Livestream Watchlist SIGN IN Create free account Markets Business Investing Tech Politics Video Watchlist Investing Club PRO Livestream watch now Share Money Movers CNBC's Angelica Peebles reports the latest news surrounding GLP-1 drugs
